{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:24:54Z","timestamp":1778653494246,"version":"3.51.4"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2015-0163_s_999_w2aab2b8c53b1b7b1aab1c14b1Aa\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diabetic neuropathy is the most common complication of diabetes mellitus, and the different drug combinations available do not provide effective pain relief. The present study was performed to observe the effect of amitripyline, duloxetine, sitagliptin, and pregabalin, and their combinations on streptozotocin (STZ)-induced diabetic neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2015-0163_s_998_w2aab2b8c53b1b7b1aab1c14b2Aa\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Diabetic neuropathy was induced by STZ, and the tail-flick test was used to assess thermal hyperalgesia before and after (at 30, 60, and 120 min) drug administration. One week after STZ administration, the blood glucose level was observed to be in the diabetic range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2015-0163_s_997_w2aab2b8c53b1b7b1aab1c14b3Aa\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Administration of all the drugs except sitagliptin increased the tail-flick latency significantly as compared to control. Further, the drugs amitriptyline, duloxetine, and pregabalin showed significant pain-relieving effect, when either two of them were administered in combination, although the different combinations had varied degree of pain relief. However, sitagliptin was observed to have no effect when administered alone or in combination with the other three drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2015-0163_s_996_w2aab2b8c53b1b7b1aab1c14b4Aa\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Therefore, the study provides new insights concerning combined therapy of pain, which further needs clinical exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2015-0163","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T16:06:47Z","timestamp":1466698007000},"page":"617-624","source":"Crossref","is-referenced-by-count":11,"title":["Drug combinations in diabetic neuropathic pain: an experimental validation"],"prefix":"10.1515","volume":"27","author":[{"given":"Chakra Dhar","family":"Tripathi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi 110029, India , Phone: +91-9818665424"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish K.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol M.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_001_w2aab2b8c53b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956\u201362.","DOI":"10.2337\/diacare.28.4.956"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_002_w2aab2b8c53b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21:976\u201382.","DOI":"10.1111\/j.1464-5491.2004.01271.x"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_003_w2aab2b8c53b1b7b1ab2b1b3Aa","unstructured":"Bhadada SK, Sahay RK, Jyostna VP, Agrawal JK. Diabetic neuropathy current concepts. J Indian Acad Clin Med 2001;2:305\u201331."},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_004_w2aab2b8c53b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758\u201365.","DOI":"10.1212\/WNL.0b013e3182166ebe"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_005_w2aab2b8c53b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes 2015;6:432\u201344.","DOI":"10.4239\/wjd.v6.i3.432"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_006_w2aab2b8c53b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726\u201332.","DOI":"10.1124\/jpet.104.075960"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_007_w2aab2b8c53b1b7b1ab2b1b7Aa","unstructured":"Kuhad A, Bishnoi M, Chopra K. Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol 2009;47:193\u20137."},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_008_w2aab2b8c53b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Vranken JH, Hollmann MW, van der Vegt MH, Kruis MR, Heesen M, Vos K, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 2011;152:267\u201373.","DOI":"10.1016\/j.pain.2010.09.005"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_009_w2aab2b8c53b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel \u03b12\u03b4-1 subunit upregulation contributes to peripheral nerve injury induced tactile allodynia. J Neurosci 2004;24:8494\u20139.","DOI":"10.1523\/JNEUROSCI.2982-04.2004"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_010_w2aab2b8c53b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Yusaf SP, Goodman J, Gonzalez IM, Bramwell S, Pinnock RD, Dixon AK, et al. Streptozocin-induced neuropathy is associated with altered expression of voltage-gated calcium channel subunit mRNAs in rat dorsal root ganglion neurones. Biochem Biophys Res Commun 2001;289:402\u20136.","DOI":"10.1006\/bbrc.2001.5943"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_011_w2aab2b8c53b1b7b1ab2b1c11Aa","unstructured":"Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 2007;3:833\u201344."},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_012_w2aab2b8c53b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Lackovic Z, Salkovic M, Kuci Z, Relja M. Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J Neurochem 1990;54:143\u20137.","DOI":"10.1111\/j.1471-4159.1990.tb13294.x"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_013_w2aab2b8c53b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Petrisic MS, Augood SJ, Bicknell RJ. Monoamine transporter gene expression in the central nervous system in diabetes mellitus. J Neurochem 1997;68:2435\u201341.","DOI":"10.1046\/j.1471-4159.1997.68062435.x"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_014_w2aab2b8c53b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 1999;80:45\u201355.","DOI":"10.1016\/S0304-3959(98)00195-X"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_015_w2aab2b8c53b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents. Regul Pept 2005;128:159\u201365.","DOI":"10.1016\/j.regpep.2004.06.001"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_016_w2aab2b8c53b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Dworkin RH, O\u2019Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237\u201351.","DOI":"10.1016\/j.pain.2007.08.033"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_017_w2aab2b8c53b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J, Baron R, Gourlay GK, Haanp\u00e4\u00e4 ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3\u201314.","DOI":"10.4065\/mcp.2009.0649"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_018_w2aab2b8c53b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007;67:569\u201385.","DOI":"10.2165\/00003495-200767040-00006"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_019_w2aab2b8c53b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 1993;53:81\u20138.","DOI":"10.1016\/0304-3959(93)90059-X"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_020_w2aab2b8c53b1b7b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Sheikh AS, Somani RS. Animal models and biomarkers of neuropathy in diabetic rodents. Indian J Pharmacol 2010;42:129\u201334.","DOI":"10.4103\/0253-7613.66833"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_021_w2aab2b8c53b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Tomi\u0107 MA, Vuckovi\u0107 SM, Stepanovi\u0107-Petrovi\u0107 RM, Micov AM, Ugresi\u0107 ND, Prostran MS, et al. Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. Eur J Pharmacol 2010;628:75\u201382.","DOI":"10.1016\/j.ejphar.2009.11.016"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_022_w2aab2b8c53b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"D\u2019Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941;72:74\u20139.","DOI":"10.1016\/S0022-3565(25)03823-6"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_023_w2aab2b8c53b1b7b1ab2b1c23Aa","unstructured":"Rakieten N, Rakieten ML, Nadkarni MR. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963;29:91\u20138."},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_024_w2aab2b8c53b1b7b1ab2b1c24Aa","unstructured":"Guo H, Yang Y, Geng Z, Zhu L, Yuan S, Zhao Y, et al. The change of insulin-like growth factor-1 in diabetic patients with neuropathy. Chin Med J 1999;112:76\u20139."},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_025_w2aab2b8c53b1b7b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Craner MJ, Klein JP, Black JA, Waxman SG. Preferential expression of IGF-1 in small DRG neurons and down-regulation following injury. Neuroreport 2002;13:1649\u201352.","DOI":"10.1097\/00001756-200209160-00016"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_026_w2aab2b8c53b1b7b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996;68:293\u20139.","DOI":"10.1016\/S0304-3959(96)03201-0"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_027_w2aab2b8c53b1b7b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Bujalska-Zadro\u017cny M, de Cord\u00e9 A, Pawlik K. Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Pharmacol Rep 2015;67:209\u201316.","DOI":"10.1016\/j.pharep.2014.08.023"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_028_w2aab2b8c53b1b7b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Said G. Diabetic neuropathy: a review. Nat Clin Pract Neurol 2007;3:331\u201340.","DOI":"10.1038\/ncpneuro0504"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_029_w2aab2b8c53b1b7b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001;53:597\u2013652.","DOI":"10.1016\/S0031-6997(24)01514-X"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_030_w2aab2b8c53b1b7b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002;50:205\u201328.","DOI":"10.1016\/S0074-7742(02)50078-7"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_031_w2aab2b8c53b1b7b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Sullivan KA, Lentz SI, Roberts Jr JL, Feldman EL. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets 2008;9:3\u201313.","DOI":"10.2174\/138945008783431763"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_032_w2aab2b8c53b1b7b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute herpetic pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci 2004;74:2619\u201326.","DOI":"10.1016\/j.lfs.2004.01.005"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_033_w2aab2b8c53b1b7b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57:153\u201360.","DOI":"10.1016\/0304-3959(94)90218-6"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_034_w2aab2b8c53b1b7b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589\u201396.","DOI":"10.1212\/WNL.37.4.589"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_035_w2aab2b8c53b1b7b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Engleman EA, Perry KW, Mayle DA, Wong DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995;12:287\u201395.","DOI":"10.1038\/sj.npp.1380263"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_036_w2aab2b8c53b1b7b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003;45:935\u201344.","DOI":"10.1016\/S0028-3908(03)00268-5"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_037_w2aab2b8c53b1b7b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotoninnorepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576\u201384.","DOI":"10.1124\/jpet.104.070656"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_038_w2aab2b8c53b1b7b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104\u201310.","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_039_w2aab2b8c53b1b7b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol 2004; 4:14.","DOI":"10.1186\/1471-2210-4-14"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_040_w2aab2b8c53b1b7b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 1999;128: 92\u2013102.","DOI":"10.1038\/sj.bjp.0702794"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_041_w2aab2b8c53b1b7b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Ryu JH, Lee PB, Kim JH, Do SH, Kim CS. Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth 2012;109:234\u20139.","DOI":"10.1093\/bja\/aes120"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_042_w2aab2b8c53b1b7b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Sharma AK, Sharma A, Kumari R, Kishore K, Sharma D, Srinivasan BP, et al. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats. J Biomed Res 2012;26:200\u201310.","DOI":"10.7555\/JBR.26.20110054"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_043_w2aab2b8c53b1b7b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Zhou JY, Zhou SW. Protection of trigonelline on experimental diabetic peripheral neuropathy. Evid Based Complement Alternat Med 2012;2012:164219.","DOI":"10.1155\/2012\/164219"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_044_w2aab2b8c53b1b7b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324\u201334.","DOI":"10.1056\/NEJMoa042580"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_045_w2aab2b8c53b1b7b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252\u201361.","DOI":"10.1016\/S0140-6736(09)61081-3"},{"key":"2025121209190947398_j_jbcpp-2015-0163_ref_046_w2aab2b8c53b1b7b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C. Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009;61:129\u201337.","DOI":"10.1159\/000186502"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jbcpp.2016.27.issue-6\/jbcpp-2015-0163\/jbcpp-2015-0163.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2015-0163\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2015-0163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:07:16Z","timestamp":1765541236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2015-0163\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,8,5]]},"published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1515\/jbcpp-2015-0163"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2015-0163","relation":{},"ISSN":["2191-0286","0792-6855"],"issn-type":[{"value":"2191-0286","type":"electronic"},{"value":"0792-6855","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,22]]}}}